Glenmark Pharmaceuticals Limited

rs,

bruary 10, 2023 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E),

₹ 123,049

Glenmark Group, today Leading Integrated Research-led Global Consolidated revenues in FY22: ₹ 123,049 mn 14th largest1 and amongst the fastest growing in the Indian market 15th largest2 generic comp

10 million

neric company by prescriptions filled in the USA 5th largest3 Indian generic company in Europe ~10 million4 COVID patients globally prescribed with FabiFlu® (favipiravir) End-to-end R&D capabilities: API

55%

diversified formulations business built organically with commercial presence in 80+ countries ~55% contribution to revenue coming from branded markets5 Dermatology, Respiratory, Oncology: clear f

82.84%

C segments in therapy areas of Dermatology, Respiratory and Oncology G qtenmauk LIFE SCIENCES (82.84% subsidiary) Focused on manufacturing and marketing of API products across all major markets glob

100%

ing and marketing of API products across all major markets globally ... ichnos ... (US based; 100% subsidiary) Innovation biotech company focused on development of novel biological molecules as po

3 million

year 2025** Zero waste to landfill at all our plant locations by the year 2027 Aspire to impact 3 million lives by 2025 Deepen global presence and deliver quality affordable in new markets Continue focu

10 %

y (excluding GLS) 5 4th Consecutive Year 1 of 4 Indian Pharma 1 of 15 Indian Companies Top 10 % ile Continuous score improvement G Glenmank Q3 and 9M FY23 Snapshot • Q3 FY23 Revenues from O

Rs. 34,639

us score improvement G Glenmank Q3 and 9M FY23 Snapshot • Q3 FY23 Revenues from Operations at Rs. 34,639 Mn with a growth of 9.2% YoY • Q3 FY23 EBITDA of Rs. 6,202 Mn with EBITDA margin of 17.9% • Q3 FY23

9.2%

ank Q3 and 9M FY23 Snapshot • Q3 FY23 Revenues from Operations at Rs. 34,639 Mn with a growth of 9.2% YoY • Q3 FY23 EBITDA of Rs. 6,202 Mn with EBITDA margin of 17.9% • Q3 FY23 Reported PAT of Rs. 2,9

Rs. 6,202

• Q3 FY23 Revenues from Operations at Rs. 34,639 Mn with a growth of 9.2% YoY • Q3 FY23 EBITDA of Rs. 6,202 Mn with EBITDA margin of 17.9% • Q3 FY23 Reported PAT of Rs. 2,908 Mn Q3 FY23 “We had yet anothe

17.9%

s at Rs. 34,639 Mn with a growth of 9.2% YoY • Q3 FY23 EBITDA of Rs. 6,202 Mn with EBITDA margin of 17.9% • Q3 FY23 Reported PAT of Rs. 2,908 Mn Q3 FY23 “We had yet another quarter with a strong perfor

Notes

4

Notes

1. The exceptional item in consolidated result is net gain of Rs 338.78 Mn arising from the sale cardiac brand Razel ( India and Nepal business), net of expenses, trade receivables, inventory write off, other reimbursable expenses and remediation cost of Monroe manufacturing site (USA). G c;L€nman.k Rs. MnQ3 FY23Q3 FY22%YoYQ2 FY23%QoQRevenues from Operations34,63931,7349.2%33,7522.6%EBITDA6,2026,932-10.5%6,216-0.2%EBITDA margin (%)17.9%21.8%18.4%Other Income (exp)764139974Exceptional gain (loss)339-1,7840Profit Before Tax (PBT)4,7103,43037.3%4,802-1.9%PBT Margin (%)13.6%10.8%14.2%Tax1,8021,0332,015Tax rate (%)38.3%30.1%42.0%Profit After Tax (PAT)2,9082,39821.3%2,7874.3%EPS (Rs)9.667.869.23R&D2,7603,030-8.9%3,300-16.4%R&D (% to sales)8.0%9.5%9.8% India Formulations Q3 FY23 growth of 11% as per IQVIA data Ranked 2nd in Respiratory for Q3 FY23 Revenue (INR Mn) 10,745 10,069 9M FY23 33% [ YoY: 6.7% QoQ: -1.6% ] 10,916 Key Highlights • Glenmark’s India business is ranked 14th1 with a market

Notes

1. As per IQVIA MAT December 2022 9M FY23 9M FY22 G Glenmank North America Formulations 9M FY23 23%• [--] YoY: 10.6% QoQ: 11.1% Revenue (INR Mn) QoQ growth of 11% Launched 3 new products in Q3 8,373 7,567 7,533 Key Highlights • Received final approval for Nicardipine Hydrochloride Capsules, final approval and launch of Sodium Phenylbutyrate Tablets USP, 500 mg • Also launched Fingolimod Capsules, 0.5 mg and a new pack size for Olmesartan 22,534 • Medoxomil Tablets USP [5 mg, 90’s]. Filed one ANDA in Q3; plans to file six-eight applications in the forthcoming quarter • Reached a settlement agreement with Pfizer for Axitinib Tablets, 1mg and 5mg (generic version of Inlyta®); market size of USD 657 Mn1 Q3 FY23 Q3 FY22 Q2 FY23 I 22,988 YoY: -2% I 13

Notes

1. IQVIA™ sales data for the 12-month period ending December 2022 9M FY23 9M FY22 G c;LE.nmank Europe Strong YoY and QoQ growth in region Ryaltris® and Salmex® / Asthmex® gain market share across CEE Revenue (INR Mn) 4,932 9M FY23 12% [ YoY: 29.5% QoQ: 30.3% ] 3,807 3,785 Key Highlights • Growth driven by markets in both regions of Western Europe (WEU) and Central & Eastern Europe (CEE) The Czech and Poland recorded strong secondary sales double digit growth • • Western European business clocked high double digit growth for Q3 • Company gained additional share in some products in the UK • • 10 new product launches across all European markets Tiogiva® also continues to grow in the WEU markets Q3 FY23 Q3 FY22 Q2 FY23 I YoY: 17.2% I 12,016 10,249 14 9M FY23 9M FY22 G c;LE.nmank ROW (Asia, MEA, LATAM and RCIS regions) 22% growth YoY Ryaltris key growth driver across major markets Revenue (INR Mn) 6,541 5,348 9M FY23 18% [ YoY: 22.3% QoQ: 6.3% ] 6,154 Key Highlights RCIS • • Asia • • Second

Notes

1. As per IQVIA MAT December 2022 9M FY23 9M FY22 G c;LE.nmank API business (Glenmark Life Sciences) 76.5% contribution from regulated markets Multiple projects completed / ongoing for capacity expansion Revenue – External Sales (INR Mn) 3,756 3,032 [ YoY: 23.9% QoQ: 0.3% ] 3,744 11% 9M FY23 Key Highlights • Consolidated sales of Rs. 5,407 Mn as against Rs. 5,225 Mn, recording a YoY growth of 3.5% • Generic API revenues in Q3 FY23 increased 5.9% QoQ and increased 1.8% YoY • CDMO revenues in Q3 FY23 decreased by 9.6% QoQ; demand is expected to pick up from Q4 FY23 onwards • DMF/CEPs filing continued across major markets in Q3 FY23, taking the total cumulative filings to 456 as on Dec 31, 2022 Q3 FY23 Q3 FY22 Q2 FY23 10,751 I YoY: 14.1% I 9,426 16 9M FY23 9M FY22 G c;LE.nmank Respiratory Strategy – Creating Global Scale • As of the end of Q3, marketing applications submitted in 58 countries across the world and commercialized in 23 markets, including major markets like the US, Europe (UK